Toronto Dominion Bank’s Akebia Therapeutics AKBA Stock Holding History

Toronto Dominion Bank’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-22	Closed	–	–	1369
2021 Q2	$0	Buy	+22	New	+$74	﹤0.01%	1362

Other funds holding AKBA

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Toronto Dominion Bank's AKBA Position: Q3 2021 in Review

Toronto Dominion Bank sold out of Akebia Therapeutics (AKBA) in Q3 2021, closing a stake of 22 shares.

Toronto Dominion Bank first reported a position in AKBA in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 126 funds tracked by Wall St. Rank hold AKBA as of Q3 2021.

Toronto Dominion Bank reported no remaining Akebia Therapeutics position as of Q3 2021 after selling out during the quarter.
Toronto Dominion Bank sold 22 Akebia Therapeutics shares in Q3 2021.
Toronto Dominion Bank first reported a position in Akebia Therapeutics in Q2 2021 and held it in 1 quarter.
Toronto Dominion Bank's Akebia Therapeutics position peaked at $0 in Q2 2021.
126 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2021.

Based on Toronto Dominion Bank's 13F filing for Q3 2021, filed 8 Nov 2021.